Dianthus Therapeutics Inc., a clinical-stage biotechnology company focused on developing antibody complement therapeutics for severe autoimmune diseases, has announced a proposed $150 million underwritten public offering. The offering consists of shares of its common stock, with an option for certain investors to choose pre-funded warrants instead. Additionally, the company may grant underwriters a 30-day option to purchase up to an additional $22.5 million of common stock. The offering is subject to market conditions, and Dianthus plans to use the net proceeds to support its preclinical and clinical development activities, as well as for general corporate purposes. Jefferies, TD Cowen, Evercore ISI, and Stifel are serving as joint book-running managers for the offering. The offering will be conducted under an effective shelf registration statement filed with the SEC.